Evidence map›Paper›PMID 30962328›Full record

ArticleAntimicrobial agents and chemotherapy2019

A Novel VIM-Type Metallo-β-Lactamase Variant, VIM-60, with Increased Hydrolyzing Activity against Fourth-Generation Cephalosporins in Pseudomonas aeruginosa Clinical Isolates in Japan.

Tomomi Hishinuma, Tatsuya Tada, Hiroki Uchida, Masahiro Shimojima, Teruo Kirikae

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Tomomi HishinumaDepartment of Microbiology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Tatsuya TadaDepartment of Microbiology, Juntendo University Graduate School of Medicine, Tokyo, Japan t-tada@juntendo.ac.jp.
Hiroki UchidaDepartment of Microbiology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Masahiro ShimojimaBML, Inc., Kawagoe, Saitama, Japan.
Teruo KirikaeDepartment of Microbiology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Juntendo University · JPKawagoe Technical High School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel VIM-type metallo-β-lactamase variant, VIM-60, was identified in multidrug-resistant

Indexed as

Anti-Bacterial Agentsbeta-LactamasesCefepimeCefpiromeCephalosporinsHumansHydrolysisJapanMicrobial Sensitivity TestsPseudomonas aeruginosaPseudomonas InfectionsAnti-Bacterial Agentsbeta-LactamasesCefepimeCefpiromeCephalosporinsfourth-generation cephalosporinsmetallo-β-lactamasePseudomonas aeruginosa

Identifiers

PMID30962328
PMCPMC6535569
OpenAlexW2929616771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.